Beacon's gene therapy for inherited blindness hits primary goal in pivotal trial

Overview

Updated Sep 21

X-linked retinitis pigmentosa gradually destroys the retinas of young men, and no treatment has ever slowed it. Beacon Therapeutics' gene therapy laru-zova is now the first to clear a pivotal trial, and the company says it will file for US approval later this year.

In a 12-month study of 85 men, 31% of those who received the high dose gained at least 15 letters on a low-light eye chart, while no untreated patients did. The result sets up a rolling biologics license application to the Food and Drug Administration and a shot at the first approved therapy for a disease where Johnson & Johnson's rival gene therapy failed last year.

Why it matters

If approved, laru-zova would be the first treatment for X-linked retinitis pigmentosa, a leading cause of blindness in young men.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

31%

High-dose responder rate

High-dose patients gaining at least 15 letters on a low-light eye chart at month 12 (p=0.0019).

Control responder rate

No untreated control patients reached the same visual acuity threshold.

VISTA trial participants

Men aged 12 to 48 with XLRP enrolled across two dose groups and an untreated control.

110

Total treated across trials

Participants treated in five years of laru-zova clinical studies, including HORIZON, SKYLINE, and DAWN.

Voices

Curated perspectives — historical figures and your fellow readers.

People Involved

Luca Baldo

Chief executive, Beacon Therapeutics

Leading Beacon toward a rolling BLA submission

Organizations Involved

Beacon Therapeutics

Clinical-stage biotechnology company

Lead developer of laru-zova for XLRP

Ophthalmic gene therapy company, formerly AGTC, focused on retinal diseases.

Syncona Ltd

Healthcare investment company

Largest Beacon shareholder at 38.4%

UK-based investor backing gene and cell therapy companies.

Johnson & Johnson

Pharmaceutical company

Competitor whose rival XLRP therapy failed

Pharmaceutical giant that abandoned a similar XLRP gene therapy in 2025.

Timeline

June 2024 September 2026

5 events Latest: September 21st, 2026 · 2 months ago

Tap a bar to jump to that date

September 2026
VISTA topline meets primary endpoint
Latest Clinical milestone

Laru-zova shows statistically significant visual acuity improvement; Beacon plans rolling BLA submission.
September 21st, 2026
September 2025
DAWN and SKYLINE results presented
Clinical data

Beacon presents DAWN 9-month and SKYLINE 36-month data at EURETINA, supporting efficacy.
September 15th, 2025
June 2025
VISTA completes enrollment

Pivotal trial finishes enrolling 85 men aged 12 to 48 with XLRP.
June 30th, 2025
May 2025
Johnson & Johnson's rival therapy fails
Competitor setback

J&J's similar XLRP gene therapy fails a pivotal trial, leaving the field to Beacon.
May 15th, 2025
June 2024
First patient treated in VISTA trial
Clinical milestone

Beacon treats the first patient in its registrational trial for laru-zova in XLRP.
June 12th, 2024

Scenarios

FDA approves laru-zova as first XLRP therapy

Likely Resolves by End of 2027

Discussed by: Beacon Therapeutics and backer Syncona, citing the VISTA result and FDA's RMAT and Fast Track designations

Beacon plans to start a rolling BLA submission in late 2026. RMAT and Fast Track designations allow expedited FDA review, and the agency already endorsed the trial's primary endpoint. Approval would make laru-zova the first therapy for XLRP, pending FDA review of safety and durability data.

Regulators ask for more data, delaying approval

Possible Resolves by Q2 2027

Discussed by: Concerns over two ocular serious adverse events in the low-dose group and durability beyond 12 months

Two serious eye-related adverse events appeared in the low-dose group, both attributed to the injection procedure. If the FDA sees a safety signal or wants longer follow-up, it could request additional studies before accepting the BLA, pushing a decision past 2027.

Beacon acquired by a larger drugmaker

Possible Resolves by End of 2027

Discussed by: Syncona, which owns 38.4% and calls the trial a key value inflection point; CEO Luca Baldo has flagged partnership or IPO options

The data shifts Beacon from a risky clinical bet to an approval candidate with a potential first-in-class retinal gene therapy. A buyer could pay a premium to skip years of in-house development in a disease where J&J just failed. Syncona's stake was valued at £183.4 million before the readout.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

December 2017

Luxturna approval (2017)

Spark Therapeutics won FDA approval for Luxturna, the first gene therapy for an inherited retinal disease, treating RPE65-mediated blindness with a single injection behind the eye.

Then

Luxturna launched at $850,000 per eye, becoming the commercial template for retinal gene therapy despite limited access.

Now

It established the regulatory and clinical path later retinal therapies follow; Roche acquired Spark in 2019.

Why this matters now

Luxturna proved the FDA would approve a one-time retinal gene therapy to restore sight — the same regulatory path laru-zova now takes.

2012-2017

Glybera withdrawal (2012-2017)

The European Medicines Agency approved Glybera in 2012 as Europe's first gene therapy, priced at roughly 1 million euros per treatment for a rare lipid disorder.

Then

Nearly unused because of high cost and a tiny patient population, its marketing authorization was withdrawn in 2017.

Now

It became a cautionary tale that regulatory approval does not guarantee commercial viability.

Why this matters now

Winning approval is not the same as building a sustainable treatment, a risk Beacon's backers weigh as laru-zova nears the FDA.